MK-677
Orally active non-peptide ghrelin mimetic. Sustained GH/IGF-1 elevation but increases appetite and water retention.
Start with a product
Pick what you have. We'll guide the rest.
Schedule, what to expect, side-effects to watch — built around your exact product.
Also: Ibutamoren · Oratrope
Orally active non-peptide ghrelin mimetic. Sustained GH/IGF-1 elevation but increases appetite and water retention.
Evidence Intelligence Score™
- Preclinical
- Pilot human
- RCT← current
- Multi-RCT
- Meta-analysis
Confidence aggregates eight dimensions of evidence — human data, safety maturity, mechanism, clinical readiness, momentum, consistency, long-term follow-up, and translational signal. It is a measure of what is known, not a recommendation. Methodology.
- Human evidenceWeight of RCT and observational data8.8
- Safety maturityFollow-up depth and adverse-event signal6.5
- Mechanism confidencePathway specificity and clarity5.9
- Clinical readinessDistance to physician-prescribable use7.8
- Research momentumRecency of indexed clinical evidence5.0
- Study consistencyEffect direction across cohorts4.4
- Long-term dataFollow-up beyond initial trial windows5.4
- Translational confidenceAnimal → human signal preservation7.5
Effects on the indexed outcomes are supported by randomized human data, with 1 citation on file.
Effect sizes outside trial populations and durations beyond the studied window remain less characterized.
Interactions outside listed contraindications, long-term safety, and effect heterogeneity across age and sex are not fully resolved.
Outlook: maturing. Expect the consensus to harden as multi-site replications publish.
Growth hormone elevation
1 study- moderateChapman IM, Bach MA, Van Cauter E, et al.
MK-677 25 mg orally once daily for up to 4 weeks restored serum IGF-1 in older adults to levels of young adults; raised mean 24h GH.
RCTn=321996unreviewed
Lean mass gain
1 study- moderateNass R, Pezzoli SS, Oliveri MC, et al.
MK-677 25 mg orally daily for 12 months increased fat-free mass by ~1.1 kg vs placebo; raised IGF-1; increased appetite/weight; transient fasting glucose elevation.
RCTn=652008unreviewed
Sleep quality
1 study- weakCopinschi G, Leproult R, Van Onderbergen A, et al.
MK-677 25 mg orally at bedtime for 7 nights increased slow-wave sleep duration ~50% and REM sleep duration ~20% in young men.
RCTn=81997unreviewed
Growth hormone elevation
1 regimenIncreased appetite; mild fluid retention.
Up to 4 weeks in this study.
Lean mass gain
1 regimenTransient fasting glucose elevation, increased appetite, mild edema; one case of congestive heart failure reported.
12 months continuous; effects on FFM appeared by 6 months.
Sleep quality
1 regimenSmall sample (n=8 young men).
Short 7-night study; long-term sleep effects not characterized.
These are observed research regimens drawn from approved labels, clinical trials, or preclinical literature — not dosing recommendations. Suggestive, never prescriptive.
- —Long-term safety beyond reported study durations.
- —Effect size in populations under-represented in the cited trials.
- —Interactions with concomitant medications outside listed contraindications.
We surface uncertainty next to every claim. Suggestive, never prescriptive — discuss with a clinician.
1 brand across three tiers.
Research-use only
1 brandSold by chemical suppliers labelled 'for laboratory research only — not for human consumption'. No pharmaceutical-grade QC, no medical oversight. Listed for transparency.